FinTechFunding

Aro Biotherapeutics: Raises $88M in Series A Financing

  • Aro Biotherapeutics, a Philadelphia, PA-based biotechnology company pioneering the development of tissue-targeted genetic medicines, closed an $88m Series A financing
  • The round led by Northpond Ventures and Cowen Healthcare Investments, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital
  • The company also intends to use the funds to advance its lead therapeutic candidates into clinical development
  • Aro is developing a unique class of Centyrin-conjugated RNA therapies to efficiently and selectively target RNA medicines to the specific site of disease
  • Centyrins are small, stable, engineered human proteins with several properties that make them suited to target receptors on specific cells
  • Then the company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates
Previous article
Conotoxia: Launched MT4 platform
Next article
JPMorgan Chase: Acquires travel and loyalty business from cxLoyalty
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

GoCardless Achieves Profitability in First Quarter

Fintech company GoCardless reports a significant financial milestone.Highlights: GoCardless has posted its first profitable quarter.The fintech company reported...
FinTech

AI Fintech Startup Round Raises $6 Million to Accelerate Growth

Funding will enhance AI-driven financial solutions for consumers.Highlights: AI fintech startup raises $6 million in funding.Investment aimed at...
FinTech

Wise Strengthens US Presence by Shifting Primary Listing

The fintech firm moves its primary share listing to the United States.Highlights: Wise to change primary listing from...
FinTech

Fed Accelerates FedNow Development for Cross-Border Payments

New consultations aim to enhance international transaction efficiency.Highlights: Federal Reserve seeks input on cross-border payment improvements.FedNow aims to...